The company conducting the first government-approved tests in people of a therapy developed using human embryonic stem cells abruptly announced that it was halting the study. George Q. Daley, HMS professor of biological chemistry and molecular pharmacology at Children’s Hospital Boston, is quoted.
Trending News
Pilots, Flight Attendants Have Greater Risk of Radiation-Related Cancer Death Than Other Professions
Findings support efforts to protect U.S. aircrews from cosmic radiation exposure
Rare Inherited Genetic Mutation Is One of Strongest Indicators Yet for Lung Cancer Risk
Influence of EGFR variant could expand screening guidelines
‘Molecular Movie’ Fills in Blanks of How Non-Enveloped Viruses Infect Cells
Cryo-ET of rotavirus answers decades-old virology question, could inform drug delivery techniques